Research programme: cancer and autoimmune disorders imaging agents - ImaginAb/Duke-NUS

Drug Profile

Research programme: cancer and autoimmune disorders imaging agents - ImaginAb/Duke-NUS

Latest Information Update: 14 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke-NUS Graduate Medical School Singapore; ImaginAb Inc
  • Class Antibody diagnostics; Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer

Most Recent Events

  • 10 Feb 2014 ImaginAb and the Duke-NUS Graduate Medical School Singapore (Duke-NUS) enter into a partnership to develop in vivo molecular imaging agents for cancer and autoimmune disorders
  • 10 Feb 2014 Early research in Autoimmune disorders (diagnosis) in Singapore (Parenteral)
  • 10 Feb 2014 Early research in Cancer (diagnosis) in Singapore (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top